Quantcast
Last updated on April 18, 2014 at 7:15 EDT

Latest Antibody Stories

2013-12-12 12:26:31

MUMBAI, December 12, 2013 /PRNewswire/ -- A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of drug gable targets for monoclonal...

2013-12-11 23:22:33

InventHelp, a leading inventor service company, is working on submitting this client's idea, the Blot Well, to companies for their review. Pittsburgh, PA (PRWEB) December 11, 2013 An inventor and researcher from Evanston, Ill., wants to improve the overall activity of studying in human-, animal- and plant membranes. "I saw a need for a way to cut down on costs of antibody staining and probing membranes," he said. Ideal for life-science and molecular-biology researchers, the...

2013-12-11 16:24:44

BOULDER, Colo. and HUNTINGTON BEACH, Calif., Dec. 11, 2013 /PRNewswire/ -- BiOptix continues support of the global antibody engineering and therapeutics research community through participation in IBC's 24th Annual Antibody Engineering & Therapeutics Conference and annual meeting of The Antibody Society, being held in Huntington Beach, CA from December 8 - 12, 2013. During the event, BiOptix will be highlighting the BiOptix Innovators Program, a unique and innovative product...

2013-12-10 08:31:29

- Data Presented as Poster at American Society of Hematology Annual Meeting and Exhibition SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been...

2013-12-05 16:25:31

- KB004, experimental anti-EphA3 monoclonal antibody therapeutic, in clinical development against hematologic cancers SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition of matter patent covering certain antibodies targeting EphA3, including KaloBios' experimental anti-cancer monoclonal antibody (mAb), KB004. The allowed claims...

2013-12-05 12:30:02

DUBLIN, Dec. 5, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/4pvg4q/global_and) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report, 2013" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

Nanomedicine May One Day Be Delivered Orally
2013-11-28 04:43:35

redOrbit Staff & Wire Reports - Your Universe Online Researchers from MIT and Brigham and Women's Hospital (BWH) have developed a new type of nanoparticle that can be absorbed through the digestive tract, bringing the cutting-edge treatment method one-step closer to being administered orally instead of through injections. While drugs delivered by nanoparticles could help treat cancer, diabetes and several other types of disease, the fact that these particles currently have to be...

2013-11-25 23:21:37

The immunoassay market is large and in some areas locked up by large IVD companies, but there is plenty of opportunity for innovators and for niche players developing antibody or antigen-based tests, according to Kalorama Information’s latest report, "The World Market for Immunoassays." New York, NY (PRWEB) November 25, 2013 The immunoassay market is large and in some areas locked up by large IVD companies, but there is plenty of opportunity for innovators and for niche...

Decoding An Individual's Immune System
2013-11-21 15:12:21

University of California - Santa Barbara You may be sensitive to gluten, but you're not sure. Perhaps you can't put your finger on a recurring malaise, and your doctor is at a loss to figure it out. A diagnostic method recently developed by UC Santa Barbara professor Patrick Daugherty can reveal — on a molecular level — the factors behind conditions thought to have environmental triggers. By decoding an individual's immune system, this elegant and accurate method can demystify,...

2013-11-21 08:26:52

Anti-leukotriene antibodies were generated with ImmuneY2(TM), Lpath's drug-discovery engine SAN DIEGO, Nov. 21, 2013 /PRNewswire/ -- Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, has used its proprietary discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes. The lead antibody, which binds to and neutralizes...